



Epidemiology Overview

Quick Start Guide

April 2022

What is Epidemiology Product?

Epidemiology is part of a suite of Clarivate DRG applications within the Company & Drug Insights Platform. It provides complete disease landscape and sizing for global markets with real world data.

Highlights include:

- ✓ 20-year, annualized patient-level forecasts that use transparent and validated bottom-up methods
- ✓ Over 200 diseases & topics covered for up to 45 countries (171 countries via extrapolation)
- ✓ 20-year, annualized patient-level forecasts that use transparent and validated bottom-up methods with risk-based trending analysis
- ✓ Interactive global dashboards with heat maps, patient flow diagrams and Epidemiology Data Slicer tool for select indications
- ✓ Real time access to epidemiology experts

Clarivate DRG Platform Login

To login to the DRG Clarivate platform, click on - <https://authentication.decisionresourcesgroup.com/login/Solutions>

Clarivate™ | DRG

About Us Contact Us

Welcome to Clarivate DRG

Whether you are a new or existing user, enter your email address

Work email address

Work email address

Get started

Having problems? Email DRG.support@clarivate.com

© 2022 Clarivate.

[Privacy policy](#) | [Terms of use](#)

*You may be asked for a password if your company is not integrated with the DRG platform

Get started using Epidemiology

The screenshot shows the Clarivate DRG website. The header includes the Clarivate logo and 'DRG' on the left, and 'About Us' and 'Contact Us' on the right. The main banner says 'Welcome [redacted] from Clarivate' and includes a note: 'Hover over any link to learn more about each product platform. Green check marks indicate partial or full content is available to you as part of your current subscription.' Below the banner, there are three columns of product categories. The first column, 'Understand the Market', has a red box around the 'Disease, Company & Drug Insights' link, which is marked with a green checkmark and a red '3'. The second column, 'Optimize Access', and the third column, 'Engage Customers', also list various platforms with green checkmarks indicating availability.

Clarivate™ | DRG

Welcome [redacted] from Clarivate

Hover over any link to learn more about each product platform. Green check marks indicate partial or full content is available to you as part of your current subscription.

Have a question? Please contact us

2

Understand the Market

Disease, Company & Drug Insights **3**

- ✓ Disease, Company & Drug Insights Platform
 - Disease Insights
 - Epidemiology
 - Biosimilars
 - Company and Drug Insights

Medtech

- ✓ Medtech Insights Platform
 - Market Insights (Medtech 360)
 - Brand Tracking (Pricetrack & Marketrack)
 - US Medical Supply Distribution

US Market Access Insights

- ✓ US Market Access Insights Platform
 - Health Plan Analysis
 - Market Overviews
 - Market Overview Interactive Database
 - National MCO Analyzer
 - Power Profiles

Optimize Access

US Formulary Data & Analytics
By Fingertip Formulary

- ✓ Account Management Dashboard
- ✓ Fingertip Accounts
- ✓ Fingertip Alerts
- ✓ Fingertip Analytics
- ✓ Fingertip Home Page (Legacy Platforms)
- ✓ Fingertip Restrictions
- ✓ Fingertip Validation Tool
- ✗ Fingertip PolicyTrack

US Lives Data & Analytics

- ✓ Employer Vantage (2020 Data)
- ✓ Employer Vantage (2021 Data)
- ✓ Integrated Payer Platform
- ✓ Managed Market Surveyor Suite (Including Pharmacy Benefit Evaluator)

Global Market Access

Engage Customers

Sales Enablement

- ✓ Fingertip Publisher

Commercial Targeting

- ✓ Healthbase
- ✓ Medtech Insights Platform
 - Commercial Targeting (Procedure Finder)
- ✗ Field Force Navigator (FFN)

Digital/Multichannel Stakeholder Engagement


- ✓ Digital Insights Platform
 - Multichannel Physician Engagement
 - Multichannel Patient Engagement
 - Multichannel Payer Engagement

1.
Go to:
<https://authentication.decisionresourcesgroup.com/login>

2.
Upon login screen, use your work e- mail address and password to login. If you experience any issue, please contact
DRG.support@clarivate.com

3.
Click on the “Disease, Company & Drug Insights” link.

Epidemiology Landing Page



Epidemiology Report

1

Table of contents

Expand all

Search within Content

Overview

Epidemiology Dashboard

Epidemiology Data Slicer BETA

Mature Markets

Emerging Markets

Americas

Europe

Middle East & Africa

Asia-Pacific

BMS Epidemiology Support

Clarivate™ | DRG

Biopharma

Search within Biopharma

ⓘ ⋮ Browse All

🔔

💬

👤

Home / Diseases /

Non-Small-Cell Lung Cancer

Notifications Off

At a Glance

Landscape & Forecast

Epidemiology

Current Treatment

Unmet Need

Access & Reimbursement

Geographic Focus: China

Meet The Team

Introduction

Last updated 1 April 2019

Key Findings

- The number of incident cases of NSCLC in the countries under study will remain relatively stable over the 20-year forecast period.
- Of the countries considered in this analysis, Japan has the highest incidence of NSCLC: 80 per 100,000 per year.
- In the United States and Europe, EGFR mutations are present in 19% of newly diagnosed cases of adenocarcinoma NSCLC. The rarer ALK translocations are present in approximately 6% of new cases of adenocarcinoma NSCLC. In Japan, these percentages are 48% and 5%, respectively.
- Of all incident cases of NSCLC in the countries under study, 44% are diagnosed as metastatic at diagnosis. Low-dose CT screening in the United States will drive a more-favorable stage distribution in this country over the forecast period.
- The average age of all incident cases of NSCLC in the countries under study is 71.

Overview

Incidence of Non-Small-Cell Lung Cancer per Year per 100,000 People of All Ages in 2019 and 2039

The incidence of NSCLC varies slightly between the countries under study, from 52 per 100,000 per year in Spain to 80 per 100,000 per year in Japan in 2019.

2

Downloads

MAIN CONTENT

Mature Markets

Full Report

All 134 Populations (Full Details)

Attachment

All 134 Populations (Geographic Summary)

Attachment

ADDITIONAL FILES

Mature Markets

Table of Contents

Meet the Team

Atul Sharma, M.P.H.

Associate Epidemiologist

Ask the Expert

View Bio

Help

1. Select Table of contents sections or enter word search term in search field to locate topic of interest. Word matches will be highlighted in yellow. Select country/region of interest from Table of contents to view corresponding report
2. Reports can be downloaded by selecting the reports of interest. The accompanying PowerPoint diagrams and Excel tables can be downloaded as separate documents

Epidemiology Dashboard

1

Table of contents

Search within Content

Overview

Epidemiology Dashboard

- Introduction
- Non-Small-Cell Lung Cancer Epidemiology Dashboard

Epidemiology Data Slicer BETA

Mature Markets

Emerging Markets

Americas

Europe

Middle East & Africa

Asia-Pacific

BMS Epidemiology Support

Clarivate | DRG

Biopharma

Search within Biopharma

Home / Diseases /

Non-Small-Cell Lung Cancer

Notifications Off

At a Glance

Landscape & Forecast

Epidemiology

Current Treatment

Unmet Need

Access & Reimbursement

Geographic Focus: China

Meet The Team

Introduction

Last updated 1 October 2020

The epidemiology dashboard allows users to view epidemiological forecasts for 45 countries all in one place, displayed in the following formats:

- A heat map view of the number of cases in each country or the corresponding incidence or prevalence estimate.
- A customizable bar chart of cases or a bubble plot demonstrating the association of the disease with GDP per capita.
- A patient flow diagram with options to display data for certain countries or regions and forecast years.

The dashboard allows users to export the diagram or chart as an image file that can easily be incorporated into internal or investor/shareholder material.

The epidemiology dashboard is available as an Excel file in the Downloads section at the top right of this page. It is available only to clients with subscriptions to all 45 countries covered by DRG Epidemiology. For subscription and entitlement queries or requests for customized versions of the epidemiology dashboard, such as including additional countries or patient populations, please contact DRG.support@clarivate.com.

Please note that you may need to update your version of Microsoft Excel to access all of the functionality in this dashboard.

2

Downloads

MAIN CONTENT

Non-Small-Cell Lung Cancer Epidemiology Dashboard Attachment

Meet the Team

Nishant Kumar, M.P.H.
Senior Epidemiologist

Ask the Expert View Bio

View all Experts

Customize Your Insights

Our ana... potential of Real World Data to

Live support ?

2

Non-Small-Cell Lung Cancer Epidemiology Dashboard


Excel | 28.18 MB

Download

1. Epidemiology dashboard comes with all access subscription to 45 countries

2. Dashboard can be downloaded in Excel format. The dashboard has 4 views: Patient Flow, Tabular, Map and Graph


Epidemiology Dashboard – Patient Flow




DRG | EPIDEMIOLOGY

Non-small-cell lung cancer (multiple subtypes) in United States, 2021

- Incident cases
 - Recurrence/progression events
 - Prevalent cases
 - Drug-treatable populations
 - Drug-treated populations
 - Estimated only for high-income countries
- a. Cause-specific deaths are not reported but can be provided on request.
- b. Unverified subtype reported only for Mature Markets



Epidemiology Dashboard – Tabular View



Epidemiology Dashboard

Tabular View

Non-small-cell lung cancer cases (Multiple Subtypes) by Country, Year and Population

Region

Americas

Asia-Pacific

Emerging Markets

Europe

Mature Markets

Middle East Africa

Geography

United States

Italy

Argentina

Belgium

Chile

Colombia

Egypt

Hong Kong

Indonesia

France

Spain

Australia

Brazil

China - Rural

Czech Republic

Finland

India - Rural

Japan

Germany

United Kingdom

Austria

Canada

China - Urban

Denmark

Greece

India - Urban

Malaysia

Subtype

Adenocarcinoma

All subtypes

Large cell

Other

Squamous cell carcinoma

Unverified

Measurement

Burden-of-illness

Drug-treatable population

Drug-treated Population

Incident population

Prevalent population

Recurrent population

Stage at diagnosis

Population

Diagnosed stage IB-II drug-treated population

Diagnosed 1st line metastatic drug-treatable population

Diagnosed 1st line metastatic drug-treated population

Diagnosed 1st line metastatic non-drug-treated population

Diagnosed 2nd line metastatic drug-treatable population

Diagnosed 2nd line metastatic drug-treated population

Diagnosed 2nd line metastatic non-drug-treated population


Diagnosed 3rd line metastatic drug-treatable population

Diagnosed 3rd line metastatic drug-treated population

	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032
Argentina																
Drug-treatable population																
Diagnosed 1st line metastatic drug-treatable population	18,876	19,119	19,346	19,555	19,832	20,101	20,362	20,613	20,852	21,154	21,452	21,744	22,070	22,390	22,772	23,153
Diagnosed 2nd line metastatic drug-treatable population	1,055	1,067	1,078	1,086	1,101	1,115	1,127	1,139	1,149	1,165	1,180	1,194	1,210	1,225	1,245	1,264
Diagnosed 3rd line metastatic drug-treatable population	1,055	1,067	1,078	1,086	1,101	1,115	1,127	1,139	1,149	1,165	1,180	1,194	1,210	1,225	1,245	1,264
Diagnosed stage IB-II drug-treatable population	2,530	2,593	2,654	2,711	2,781	2,851	2,919	2,987	3,052	3,129	3,209	3,287	3,372	3,457	3,552	3,651
Diagnosed stage III drug-treatable population	5,489	5,581	5,669	5,748	5,850	5,948	6,044	6,138	6,227	6,336	6,441	6,545	6,660	6,776	6,911	7,047
Drug-treated Population																
Diagnosed stage IB-II drug-treated population	135	138	141	143	147	150	154	157	160	164	168	171	176	180	184	189
Diagnosed 1st line metastatic drug-treated population	1,055	1,067	1,078	1,086	1,101	1,115	1,127	1,139	1,149	1,165	1,180	1,194	1,210	1,225	1,245	1,264
Diagnosed 2nd line metastatic drug-treated population	1,055	1,067	1,078	1,086	1,101	1,115	1,127	1,139	1,149	1,165	1,180	1,194	1,210	1,225	1,245	1,264
Diagnosed 3rd line metastatic drug-treated population	1,055	1,067	1,078	1,086	1,101	1,115	1,127	1,139	1,149	1,165	1,180	1,194	1,210	1,225	1,245	1,264
Diagnosed stage III drug-treated population	349	354	358	362	367	372	377	382	386	392	397	402	408	413	420	427
Incident population																
Diagnosed ALK+ve incident cases	9,854	10,018	10,170	10,311	10,495	10,673	10,845	11,011	11,172	11,374	11,574	11,772	11,988	12,200	12,453	12,704
Diagnosed ALK-ve incident cases	13,639	13,871	14,086	14,283	14,545	14,796	15,039	15,273	15,500	15,788	16,074	16,357	16,660	16,958	17,314	17,668


Select Region, Geography, Subtype, Measurement, Population filters as indicated to view historical, current and forecast cases per population

Epidemiology Dashboard – Map View




Select Subtype, Measurement, Population filters as indicated to incidence rate and case heat maps

Epidemiology Dashboard – Graph View



Epidemiology Data Slicer



1. Epidemiology Data Slicer is an interactive visualization dashboard and a data slicer for select diseases so that you can quickly access all your Epidemiology content in one place. For more detailed information, click the link below: [Data Slicer Quick Start Guide](#)

Epidemiology Reports by Region

1

2

Clarivate | DRG

Biopharma

Search within Biopharma

Browse All

Home / Diseases /

Non-Small-Cell Lung Cancer

At a Glance

Landscape & Forecast

Epidemiology

Current Treatment

Unmet Need

Access & Reimbursement

Geographic Focus: China

Meet The Team

Table of contents

Search within Content

Overview

Extrapolated Worldwide Coverage

Epidemiology Dashboard

Epidemiology Data Slicer

Mature Markets

Introduction

Epidemiology Data

Methods

Reference Materials

Emerging Markets

Americas

Europe

Middle East & Africa

Asia-Pacific

Introduction

Last updated 1 April 2019

Key Findings

The number of incident cases of NSCLC in the countries under study will remain relatively stable over the 20-year forecast period.

Of the countries considered in this analysis, Japan has the highest incidence of NSCLC: 80 per 100,000 per year.

In the United States and Europe, EGFR mutations are present in 19% of newly diagnosed cases of adenocarcinoma NSCLC. The rarer ALK translocations are present in approximately 6% of new cases of adenocarcinoma NSCLC. In Japan, these percentages are 48% and 5%, respectively.

Of all incident cases of NSCLC in the countries under study, 44% are diagnosed as metastatic at diagnosis. Low-dose CT screening in the United States will drive a more-favorable stage distribution in this country over the forecast period.

The average age of all incident cases of NSCLC in the countries under study is 71.

Overview

Incidence of Non-Small-Cell Lung Cancer per Year per 100,000 People of All Ages in 2019 and 2039

The incidence of NSCLC varies slightly between the countries under study, from 52 per 100,000 per year in Spain to 80 per 100,000 per year in Japan in 2019.

United States

Japan

France

2019

2039

Downloads

MAIN CONTENT

Mature Markets Full Report

All 134 Populations (Full Details) Attachment

All 134 Populations (Geographic Summary) Attachment

ADDITIONAL FILES

Mature Markets Table of Contents

Meet the Team

Atul Sharma, M.P.H. Associate Epidemiologist

Ask the Expert View Bio

View all Experts

Customize Your Insights

Our analytic experts harness the potential of Real-World Evidence

Help

1. Click on region of interest from Table of contents to view corresponding Epidemiology report
2. Region reports include the following sections:
 - Epidemiology Data
 - Methods
 - Reference Materials

Epidemiology Data

Clarivate | DRG

Biopharma

Search within Biopharma

q

ⓘ Browse All

🔔

💬

👤

Home / Diseases /

Non-Small-Cell Lung Cancer

Notifications Off

At a Glance

Landscape & Forecast

Epidemiology

Current Treatment

Unmet Need

Access & Reimbursement

Geographic Focus: China

Meet The Team

Table of contents

Expand all

Search within Content

q

Overview

Extrapolated Worldwide Coverage

Epidemiology Dashboard

Epidemiology Data Slicer BETA

Mature Markets

Introduction

Epidemiology Data

Methods

Reference Materials

Emerging Markets

Americas

Europe

Middle East & Africa

Asia-Pacific

Mature Markets

Epidemiology Data for **Select Population**

Top-line epidemiology

Diagnosed NSCLC incident cases

Key Populations

Diagnosed NSCLC stage IA incident cases

Diagnosed NSCLC stage IB incident cases

Diagnosed NSCLC stage IIA incident cases

Diagnosed NSCLC stage IIB incident cases

Diagnosed NSCLC stage IIIA incident cases

Diagnosed NSCLC stage IIIB incident cases

Diagnosed NSCLC stage IV incident cases

Adenocarcinoma by Stage

1

📄 Downloads

👤 population to view our epidemiology data

Previous section Introduction

Next section Methods

© 2022 Clarivate

Legal center | Privacy center | Privacy notice (updated) | Cookie policy

Live support

?

1. Select from Population filter drop down list to view population report

Epidemiology Data

Clarivate | DRG

Biopharma

Search within Biopharma

Browse All

Home / Diseases /

Non-Small-Cell Lung Cancer

Notifications Off

At a Glance

Landscape & Forecast

Epidemiology

Current Treatment

Unmet Need

Access & Reimbursement

Geographic Focus: China

Meet The Team

Table of contents

Expand all

Search within Content

Overview

Extrapolated Worldwide Coverage

Epidemiology Dashboard

Epidemiology Data Slicer

Mature Markets

Introduction

Epidemiology Data

Methods

Reference Materials

Emerging Markets

Americas

Europe

Middle East & Africa

Asia-Pacific

Mature Markets

Downloads

Epidemiology Data for Diagnosed NSCLC incident cases

Full Detail

By Geography

By Age Group

By Gender

By Age & Gender

Methods

1

FILTER DATA

All Geographies

All Years

2

Display

Cases

Diagnosed NSCLC incident cases by Geography (Cases)

Download Table

Geography	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039
United States	163,648	165,634	167,608	169,979	172,507	174,567	176,637	178,802	180,705	182,384	183,772	184,993	185,997	187,377	188,584	188,611	188,622	188,042	186,868	185,014	182,091	179,755	178,308	177,839
France	36,884	37,130	37,522	37,815	37,928	37,998	38,058	38,290	38,727	39,218	39,550	39,817	40,109	40,380	40,763	41,153	41,320	41,310	41,221	40,949	40,546	40,252	39,939	39,586
Germany	48,841	49,241	49,713	50,183	50,555	50,861	51,182	51,595	52,094	52,554	52,909	53,208	53,423	53,605	53,834	53,979	54,127	54,142	53,907	53,493	52,912	52,380	51,989	51,682
Italy	37,701	38,028	38,397	38,778	39,182	39,479	39,751	40,036	40,362	40,841	41,406	41,989	42,580	43,167	43,746	44,242	44,741	45,200	45,588	45,908	46,096	46,246	46,341	46,412
Spain	23,343	23,563	23,795	24,018	24,190	24,256	24,299	24,323	24,353	24,370	24,360	24,328	24,293	24,273	24,303	24,346	24,426	24,524	24,609	24,676	24,672	24,647	24,608	24,558
United Kingdom	40,076	40,704	41,330	41,581	41,835	42,744	43,957	44,322	44,837	45,253	46,625	46,339	46,866	48,088	48,197	48,221	46,851	48,498	47,836	48,023	48,151	48,261	48,380	48,495
Japan	101,367	101,640	101,922	102,137	102,282	102,295	102,203	102,227	102,207	102,089	101,793	101,243	100,621	99,906	99,145	98,275	97,219	95,570	93,357	90,482	87,220	84,467	82,347	81,094
Total	451,860	455,940	460,287	464,491	468,479	472,200	476,087	479,595	483,285	486,709	490,415	491,917	493,889	496,796	498,572	498,827	497,306	497,286	493,386	488,545	481,688	476,008	471,912	469,666

Diagnosed NSCLC incident cases by Geography (Cases)

Download Chart

Help

1. Toggle between tabs to view population report by:

- Full detail
- Geography
- Age Group
- Gender
- Age & Gender
- Methods

2. Toggle between Cases and Units to change data table display units

Epidemiology Methods

Clarivate | DRG

Biopharma

Search within Biopharma

Browse All

Home / Diseases /

Non-Small-Cell Lung Cancer

Notifications Off

At a Glance

Landscape & Forecast

Epidemiology

Current Treatment

Unmet Need

Access & Reimbursement

Geographic Focus: China

Meet The Team

Table of contents

Expand all

Search within Content

Overview

Extrapolated Worldwide Coverage

Epidemiology Dashboard

Epidemiology Data Slicer

Mature Markets

Introduction

Epidemiology Data

Methods

Lifetime DALYs Gained

Newly Diagnosed Incidence

Stage Distribution

Mutation Status

Recurrent Incidence

Diagnosed Prevalence

Drug-Treatable Population

Drug-Treated Population

Reference Materials

Emerging Markets

Americas

Europe

Middle East & Africa

Asia-Pacific

Methods

Last updated 1 April 2019

Lifetime DALYs Gained

Disease Definition

DALYs are a disease-specific measure of burden, where one DALY represents one year of healthy life lost due to a disease. DALYs are gained when an individual becomes diseased/disabled and loses a year(s) of life that would have otherwise been lived in perfect health. Lifetime DALYs gained is the sum of all the DALYs gained throughout the lifetime of a diseased population.

While DALYs measure disease burden, QALYs measure utility or health status. If an equal trade-off between disability and utility is assumed, then lifetime DALYs gained due to disease will be approximately the same as the lifetime number of QALYs lost due to disease.

Methods

We base our estimates of lifetime DALYs gained on age- and disease-specific DALYs gained per case of disease reported by the Institute of Health Metrics and Evaluation (IHME, 2017). We then applied these estimates to DRG's estimated case counts in each year of the forecast period.

Our forecast period for lifetime DALYs gained is limited to ten years because the possible introduction of new treatments or technologies to reduce the disabling impact of the disease cannot reasonably be assessed beyond this period. For extended forecasts or for DALY or QALY estimates that can be used to calculate incremental cost-effectiveness ratios or other economic models, contact DRG.support@clarivate.com.

Newly Diagnosed Incidence

Disease Definition

We define a case of lung cancer using ICD-10 code C34. We identify cases of NSCLC by excluding cases with the histology codes 8041-8045 because these codes represent SCLC (WHO, 2000).

We group NSCLC and unverified tumors into the following histologically defined groups:

Squamous cell carcinoma: ICD-O-3 codes 8050-8078, 8083-8084.

Downloads

MAIN CONTENT

Mature Markets Full Report

All 134 Populations (Full Details) Attachment

All 134 Populations (Geographic Summary) Attachment

ADDITIONAL FILES

Mature Markets Table of Contents

Meet the Team

Atul Sharma, M.PH. Associate Epidemiologist

Ask the Expert View Bio

View all Experts

Customize Your Insights

Our analysis is based on the potential of our solutions to reveal customized insights for our

Live support


1.
- Methods section describes the following methods used to create the report:
- Newly Diagnosed Incidence
 - Stage Distribution
 - Mutation Status
 - Recurrent Incidence
 - Diagnosed Prevalence
 - Drug Treatable Population
 - Drug Treated Population

Epidemiology Methodology



1. Literature Search

- Search expression and databases/sources to search (in agreement with client)
- Deliverable: Search results summary



2. Critical Appraisal

- Establish appraisal/extraction criteria and evidence quality standards (in agreement with client)
- Deliverable: Evidence summary, PRISMA diagram



3. Preliminary Estimates

- Unvalidated, non-benchmarked estimates
- Deliverables: preliminary case counts/parameter estimates

Epidemiology Methodology




4. Forecast Model

- Assessment and incorporation of evolving risk factors or medical practice into forecast model
- Deliverable: forecast assumptions/parameters



5. Benchmarking and Validation

- Comparison of forecast model output with third-party estimates, sensitivity analysis
- Deliverable: Validation/benchmarking results



6. Peer Review and QC


- Internal peer review and QC procedure
- Deliverables: final project deliverables

Epidemiology Methodology



7. Real World Data (RWD)

- De-identified claims and EHR data are normalized, mastered, cleansed and incorporated into Clarivate's in-house repository
- Deliverable: Clarivate's integrated RWD product



Epidemiology Reference Materials

Clarivate[®] | DRG

Biopharma

Search within Biopharma

Home / Diseases /

Non-Small-Cell Lung Cancer

Notifications Off

At a Glance

Landscape & Forecast

Epidemiology

Current Treatment

Unmet Need

Access & Reimbursement

Geographic Focus: China

Meet The Team

Table of contents

Expand all

Search within Content

Overview

Extrapolated Worldwide Coverage

Epidemiology Dashboard

Epidemiology Data Slicer

Mature Markets

- Introduction
- Epidemiology Data
- Methods
- Reference Materials
 - Literature Review
 - Risk/Protective Factors
 - Bibliography
 - Glossary

Emerging Markets

Americas

Europe

Middle East & Africa

Asia-Pacific

Reference Materials

Last updated 1 April 2019

Literature Review

We systematically review the published literature, including online registries and surveys, using a systematic search with a defined date range, for the most representative epidemiological data on NSCLC.

We summarize the results of our systematic review for the epidemiological estimates of risk, prevalence, or survival that are used directly in our forecast model in the "Studies Included in the Analysis of NSCLC" table. How we used these estimates and to which countries they were applied are discussed in the text and summarized in the "Key Sources" table. We report the most relevant sources not used and the reason for not using them in the "Studies Excluded from the Analysis of NSCLC" table.

Studies Included in the Analysis of NSCLC

Study	Measurement	Setting	Period	Risk/Proportion
NCI, 2019	Diagnosed incidence of adenocarcinoma NSCLC	United States	2000-2016	21.8 per 100k/year
ECIS, 2018	Diagnosed incidence of adenocarcinoma NSCLC	France	2003-2013	22.8 per 100k/year
RKI, 2016	Diagnosed incidence of adenocarcinoma NSCLC	Germany	2003-2014	16.5 per 100k/year
IARC XI, 2019	Diagnosed incidence of adenocarcinoma NSCLC	Italy	2008-2012	15.6 per 100k/year
IARC XI, 2019	Diagnosed incidence of adenocarcinoma NSCLC	Spain	2008-2012	13.9 per 100k/year
ONS, 2019	Diagnosed incidence of adenocarcinoma NSCLC	United Kingdom	2000-2016	14.1 per 100k/year
NCC, 2019	Diagnosed incidence of adenocarcinoma NSCLC	Japan	2000-2014	23 per 100k/year
NCI, 2019	Diagnosed incidence of SCCNSCLC	United States	2000-2016	10.2 per 100k/year
ECIS, 2018	Diagnosed incidence of SCCNSCLC	France	2003-2013	12.1 per 100k/year
RKI, 2016	Diagnosed incidence of SCCNSCLC	Germany	2003-2014	10.7 per 100k/year
IARC XI, 2019	Diagnosed incidence of SCCNSCLC	Italy	2008-2012	8.3 per 100k/year
IARC XI, 2019	Diagnosed incidence of SCCNSCLC	Spain	2008-2012	12 per 100k/year
ONS, 2019	Diagnosed incidence of SCCNSCLC	United Kingdom	2000-2016	11.6 per 100k/year
NCC, 2019	Diagnosed incidence of large-cell NSCLC	Japan	2000-2014	9.6 per 100k/year

Downloads

MAIN CONTENT

Mature Markets Full Report

All 134 Populations (Full Details) Attachment

All 134 Populations (Geographic Summary) Attachment

ADDITIONAL FILES

Mature Markets Table of Contents

Meet the Team

Atul Sharma, M.PH. Associate Epidemiologist

Ask the Expert View Bio

View all Experts

Customize Your Insights

Our analysis reveals the potential to reveal customized insights for our

Live support

1.
- Reference materials includes:
- Literature review
 - Studies excluded
 - Risk / protective factors
 - Bibliography
 - Glossary

Alerts Request

Clarivate™ | DRG

Biopharma ▾


Search within Biopharma


Q


≡

Browse

1







Home /

My Favorite Topics

View My Notifications

Diseases & Other Topics

Medtech

Q

Start typing a disease or topic

Autoimmune & Inflammation

☐ Dermatology

☐ Acne

☐ Actinic Keratosis

☐ Alopecia

☐ Atopic Dermatitis/Atopic Eczema

☐ Dermatitis/Eczema

☐ Hidradenitis Suppurativa

☐ Psoriasis

☐ Urticaria

☐ Respiratory

☐ Acute Respiratory Distress Syndrome

☐ Allergic Rhinitis

☐ Asthma

☐ Chronic Obstructive Pulmonary Disease

☐ Cystic Fibrosis

☐ Idiopathic Pulmonary Fibrosis

☐ Obstructive Sleep Apnea

☐ Sarcoidosis

☐ Rheumatology

☐ Axial Spondyloarthritis

☐ Juvenile Idiopathic Arthritis

☐ Osteoarthritis

☐ Rheumatoid Arthritis

☐ Scleroderma (Systemic Sclerosis)


☐ Sjogren's Syndrome

My Favorites

Email Preferences

☐ Email me when there is updated content or new content published matching my favorites

Save Settings



1.
To request email alerts of Epidemiology report key updates, select the bell icon

2.
Select the medical device markets that you are subscribed to, then select the “Email Preferences” checkbox, then select the “Save Settings” button

Clarivate™

© 2022 Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.

Support Requests

Clarivate™ | DRG

Biopharma

Search within Biopharma

Q

ⓘ ≡ Browse All

🔔

💬

👤

Home / Diseases /

Non-Small-Cell Lung Cancer

🔔 Notifications Off

At a Glance

Landscape & Forecast

Epidemiology

Current Treatment

Unmet Need

Access & Reimbursement

Geographic Focus: China

Meet The Team

Table of contents

Expand all

Search within Content

Q

Overview

Epidemiology Dashboard

Epidemiology Data Slicer

BETA

Mature Markets

Introduction

Epidemiology Data

Methods

Reference Materials

Emerging Markets

Americas

Europe

Middle East & Africa

Asia-Pacific

BMS Epidemiology Support

Introduction

🕒 Last updated 1 April 2019

Key Findings

- The number of incident cases of NSCLC in the countries under study will remain relatively stable over the 20-year forecast period.
- Of the countries considered in this analysis, Japan has the highest incidence of NSCLC: 80 per 100,000 per year.
- In the United States and Europe, EGFR mutations are present in 19% of newly diagnosed cases of adenocarcinoma NSCLC. The rarer ALK translocations are present in approximately 6% of new cases of adenocarcinoma NSCLC. In Japan, these percentages are 48% and 5%, respectively.
- Of all incident cases of NSCLC in the countries under study, 44% are diagnosed as metastatic at diagnosis. Low-dose CT screening in the United States will drive a more-favorable stage distribution in this country over the forecast period.
- The average age of all incident cases of NSCLC in the countries under study is 71.

Overview

Incidence of Non-Small-Cell Lung Cancer per Year per 100,000 People of All Ages in 2019 and 2039

The incidence of NSCLC varies slightly between the countries under study, from 52 per 100,000 per year in Spain to 80 per 100,000 per year in Japan in 2019.

Downloads

MAIN CONTENT

Mature Markets Full Report

All 134 Populations (Full Details) Attachment

All 134 Populations (Geographic Summary) Attachment

ADDITIONAL FILES

Mature Markets Table of Contents

1

Meet the Team

Atul Sharma, M.P.H.
Associate Epidemiologist

Ask the Expert View Bio

🗨 Live support

?

1. Select “Live Support” for real-time access to in-house epidemiology expert (with Epidemiology module subscription). If you have additional questions or support requests, select “Ask the Expert “ or “Contact Us” located under the “?” (Resources & updates) icon



Have a Question?

DRG.support@clarivate.com
clarivate.com

About Clarivate

Clarivate™ is a global leader in providing solutions to accelerate the lifecycle of innovation. Our bold mission is to help customers solve some of the world's most complex problems by providing actionable information and insights that reduce the time from new ideas to life-changing inventions in the areas of science and intellectual property. We help customers discover, protect and commercialize their inventions using our trusted subscription and technology-based solutions coupled with deep domain expertise. For more information, please visit clarivate.com.

© 2022 Clarivate. All rights reserved. Reproduction or redistribution of Clarivate content, including by framing or similar means, is prohibited without the prior written consent of Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.